These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 17333333

  • 1. BARD1 and breast cancer in Poland.
    Jakubowska A, Cybulski C, Szymańska A, Huzarski T, Byrski T, Gronwald J, Debniak T, Górski B, Kowalska E, Narod SA, Lubiński J.
    Breast Cancer Res Treat; 2008 Jan; 107(1):119-22. PubMed ID: 17333333
    [Abstract] [Full Text] [Related]

  • 2. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [Abstract] [Full Text] [Related]

  • 3. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
    Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R.
    J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
    [Abstract] [Full Text] [Related]

  • 4. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.
    Vahteristo P, Syrjäkoski K, Heikkinen T, Eerola H, Aittomäki K, von Smitten K, Holli K, Blomqvist C, Kallioniemi OP, Nevanlinna H.
    Eur J Hum Genet; 2006 Feb; 14(2):167-72. PubMed ID: 16333312
    [Abstract] [Full Text] [Related]

  • 5. The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis.
    Johnatty SE, Beesley J, Chen X, Hopper JL, Southey MC, Giles GG, Goldgar DE, Chenevix-Trench G, Spurdle AB, Australian Ovarian Cancer Study Group, Kathleen Cuningham Consortium for Research in Familial Breast Cancer.
    Breast Cancer Res Treat; 2009 May; 115(1):145-50. PubMed ID: 18481171
    [Abstract] [Full Text] [Related]

  • 6. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
    Cybulski C, Lubiński J, Wokołorczyk D, Kuźniak W, Kashyap A, Sopik V, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Górski B, Dębniak T, Narod SA, Akbari MR.
    Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
    [Abstract] [Full Text] [Related]

  • 7. The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.
    Gonzalez-Hormazabal P, Reyes JM, Blanco R, Bravo T, Carrera I, Peralta O, Gomez F, Waugh E, Margarit S, Ibañez G, Santos JL, Jara L.
    Mol Biol Rep; 2012 Aug; 39(8):8091-8. PubMed ID: 22544576
    [Abstract] [Full Text] [Related]

  • 8. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
    Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA, GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P, SWE-BRCA, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR.
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Breast cancer predisposing alleles in Poland.
    Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbański K, Mituś J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, Tołoczko-Grabarek A, Medrek K, Masojć B, Mierzejewski M, Kowalska E, Narod SA, Lubiński J.
    Breast Cancer Res Treat; 2005 Jul; 92(1):19-24. PubMed ID: 15980987
    [Abstract] [Full Text] [Related]

  • 12. Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls.
    Ding DP, Zhang Y, Ma WL, He XF, Wang W, Yu HL, Guo YB, Zheng WL.
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1463-8. PubMed ID: 21809034
    [Abstract] [Full Text] [Related]

  • 13. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.
    Sauer MK, Andrulis IL.
    J Med Genet; 2005 Aug; 42(8):633-8. PubMed ID: 16061562
    [Abstract] [Full Text] [Related]

  • 14. BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
    Wiener D, Gajardo-Meneses P, Ortega-Hernández V, Herrera-Cares C, Díaz S, Fernández W, Cornejo V, Gamboa J, Tapia T, Alvarez C, Carvallo P.
    Breast Cancer Res Treat; 2015 Oct; 153(3):669-78. PubMed ID: 26395808
    [Abstract] [Full Text] [Related]

  • 15. Mutational analysis of BARD1 in familial breast cancer patients in Japan.
    Ishitobi M, Miyoshi Y, Hasegawa S, Egawa C, Tamaki Y, Monden M, Noguchi S.
    Cancer Lett; 2003 Oct 08; 200(1):1-7. PubMed ID: 14550946
    [Abstract] [Full Text] [Related]

  • 16. Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
    Ratajska M, Antoszewska E, Piskorz A, Brozek I, Borg Å, Kusmierek H, Biernat W, Limon J.
    Breast Cancer Res Treat; 2012 Jan 08; 131(1):89-97. PubMed ID: 21344236
    [Abstract] [Full Text] [Related]

  • 17. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.
    Fabbro M, Schuechner S, Au WW, Henderson BR.
    Exp Cell Res; 2004 Aug 15; 298(2):661-73. PubMed ID: 15265711
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
    Wu JY, Vlastos AT, Pelte MF, Caligo MA, Bianco A, Krause KH, Laurent GJ, Irminger-Finger I.
    Int J Cancer; 2006 Mar 01; 118(5):1215-26. PubMed ID: 16152612
    [Abstract] [Full Text] [Related]

  • 20. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, Aleksakhina SN, Mitiushkina NV, Gorodnova TV, Bessonov AA, Togo AV, Lubiński J, Cybulski C, Jakubowska A, Dörk T, Imyanitov EN.
    Breast Cancer Res Treat; 2014 Jun 01; 145(2):553-62. PubMed ID: 24800916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.